Soligenix shares rise 15.45% premarket after positive Phase 2a psoriasis gel trial results show clinical success and improved tolerability.

Soligenix Inc. (NASDAQ:SNGX) surged 15.45% in premarket trading following the announcement of positive Phase 2a trial results for its SGX302 gel formulation in treating mild-to-moderate psoriasis. The optimized gel demonstrated clinical success in the third cohort, with one patient achieving an "Almost Clear" status via the Investigator Global Assessment (IGA) and over 50% improvement in Psoriasis Area and Severity Index (PASI) scores. The treatment was well-tolerated, with no drug-related adverse events, and showed comparable or improved outcomes versus the prior ointment formulation. The results reinforce SGX302’s potential as a non-carcinogenic, non-mutagenic photodynamic therapy targeting a $40 billion global psoriasis market by 2027. Additional news, including SGX945’s positive Phase 2a data for Behçet’s Disease, further underscored the company’s pipeline strength, but the psoriasis trial’s implications for a larger commercial opportunity were the primary catalyst for the premarket rally.